Related references
Note: Only part of the references are listed.Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032
Giles W. Robinson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer
Jillian Brechbiel et al.
CANCER TREATMENT REVIEWS (2014)
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Aleksandar Sekulic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding
Richard A. Graham et al.
CLINICAL CANCER RESEARCH (2011)
Pharmacokinetic-Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation
Harvey Wong et al.
CLINICAL CANCER RESEARCH (2011)
Following the Hedgehog to New Cancer Therapies.
Andrzej A. Dlugosz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Mechanisms of Hedgehog pathway activation in cancer and implications for therapy
Suzie J. Scales et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2009)
Targeting the Hedgehog pathway in cancer
Lee L. Rubin et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Share Paper
